PCM
ESPR

Pinz Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Pinz Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,300
Closed -$184K – 410
2021
Q3 		$184K Buy
+15,300
New +$223K 0.08% 98

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Pinz Capital Management's ESPR Position: Q4 2021 in Review

Pinz Capital Management sold out of Esperion Therapeutics (ESPR) in Q4 2021, closing a stake of 15,300 shares — an estimated $184K sold.

Pinz Capital Management first reported a position in ESPR in Q3 2021 and held it in 1 quarter. The position peaked at $184K in Q3 2021. 133 funds tracked by Wall St. Rank hold ESPR as of Q4 2021.

  • Pinz Capital Management reported no remaining Esperion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Pinz Capital Management sold 15,300 Esperion Therapeutics shares in Q4 2021, an estimated $184K.
  • Pinz Capital Management first reported a position in Esperion Therapeutics in Q3 2021 and held it in 1 quarter.
  • Pinz Capital Management's Esperion Therapeutics position peaked at $184K in Q3 2021.
  • 133 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2021.

Based on Pinz Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.